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ABSTRACT
A retrospective case series study was performed in a 30-bed general intensive care unit (ICU) of a
tertiary care hospital to assess the effectiveness and safety of colistin in 43 critically ill patients with ICU-
acquired infections caused by multiresistant Gram-negative bacteria. Various ICU-acquired infections,
mainly pneumonia and bacteraemia caused by multiresistant strains of Pseudomonas aeruginosa and ⁄ or
Acinetobacter baumannii, were treated with colistin. Good clinical response (cure or improvement) was
noted in 74.4% of patients. Deterioration of renal function occurred in 18.6% of patients during colistin
therapy. Nephrotoxicity was elevated significantly in those patients with a history of renal failure
(62.5%). All-cause mortality amounted to 27.9%. In this group of critically ill patients, an age of
>50 years (OR, 5.4; 95% CI 1.3–24.9) and acute renal failure (OR, 8.2; 95% CI 2.9–23.8) were independent
predictors of mortality. Colistin should be considered as a treatment option in critically ill patients with
infection caused by multiresistant Gram-negative bacilli.
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INTRODUCTION
Inadequate therapy for infections acquired in the
intensive care unit (ICU) is associated with
increased mortality [1], but the frequent use of
broad-spectrum antibiotics means that the ICU
environment has become a theatre for selection of
multiresistant microorganisms. Infections caused
by multiresistant Gram-negative bacteria such as
Pseudomonas aeruginosa and Acinetobacter bauman-
nii have become a serious problem worldwide [2].
Colistin, an antibiotic first discovered almost
60 years ago, has not been used greatly since the
early 1980s because of its nephrotoxicity, except in
patients with cystic fibrosis [3,4]. However, it has
been reintroduced recently in clinical practice as a
last resort for treatment of nosocomial infections
caused by multiresistant bacteria [5–10]. The
present study describes a retrospective analysis
of colistin use in a group of critically ill ICU
patients suffering from ICU-acquired infections
caused by multiresistant strains of P. aeruginosa
and A. baumannii. The study was designed to
evaluate the effectiveness and safety of colistin,
and to identify independent risk factors of
mortality.
PATIENTS AND METHODS
Design and setting
The study was designed as a retrospective case series of
critically ill patients with ICU-acquired infections caused by
multiresistant Gram-negative bacteria treated with intraven-
ous colistin. It was conducted at the 30-bed general ICU of the
Henry Dunant Hospital, Athens, Greece (c.2000 patients
admitted to the ICU annually). The study was approved by
the Institutional Review Board of the hospital.
Patient identification
From 1 July 2001 to 1 December 2003, colistin-treated patients
were identified through the electronic databases for antibiotic
use and in-vitro antimicrobial susceptibility results. All adult
patients with multiresistant (except to colistin) Gram-negative
bacterial infections requiring treatment with intravenous
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colistin were eligible for the study, including patients with
chronic renal failure. Intermediate susceptibility to other
antibiotics, e.g., carbapenems, was considered as resistance.
Route of colistin administration and dosage
All patients in the study received intravenous colistin sulph-
omethate sodium at a dose of 3 million units every 8 h for at
least 48 h, with 1 mg of the colistin used being approximately
equal to 12 500 IU (Forest Laboratories, Bexley, UK) or
13 333 IU (Norma, Athens, Greece). Dosage adjustments were
made according to creatinine clearance in patients with renal
failure. For patients with serum creatinine of up to
1.2 mg ⁄ 100 mL, 1.3–1.5 mg ⁄ 100 mL, 1.6–2.5 mg ⁄ 100 mL, and
>2.6 mg ⁄ 100 mL, the unit dose of colistin was 3 million IU
administered every 8, 12, 24 and 36 h, respectively. For
patients receiving dialysis treatment, the dosage was adjusted
to 1 million IU after each period of dialysis.
Microbiological methods
Standard media and techniques for bacterial isolation and
identification were used. Antibiotic susceptibility was deter-
mined both by disk diffusion and by microdilution tests (Vitek;
bioMe´rieux, Hazelwood, MO, USA). Using the disk diffusion
method with a colistin 10 lg disk (Oxoid, Basingstoke, UK), an
inhibition zone of ‡11 mm was accepted as the cut-off to
determine susceptibility. Quality control was performed
according to NCCLS recommendations.
Data collection
For each patient, clinical data were extracted from the medical
record and entered into a database. The following information
was collected: demographics, dates of admission and dis-
charge, transfer from another institution, medical history,
previous surgery, infection on ICU admission, Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) II scores [11],
previous nosocomial infections, clinical course, ICU length of
stay, hospital discharge diagnoses, and outcome. Data on
positive bacterial cultures, antibiotic susceptibilities, antibiotics
administered, dates and sites of the first isolation of multire-
sistant bacteria, subsequent culture results, and the duration of
colistin therapy were also collected. Side-effects related to
colistin, organ dysfunctions, and the development of septic
shock during the evolution of nosocomial infection leading to
administration of colistin were recorded, as well as the
concomitant use of other drugs that could potentially cause
nephrotoxicity. Two independent investigators determined the
type of infection and the outcome.
Definitions
Standard definitions were used for co-morbid conditions (e.g.,
diabetes mellitus, chronic obstructive pulmonary disease, etc.).
Diagnosis of pneumonia required the presence of new,
persistent and otherwise unexplained pulmonary infiltrates
appearing on chest radiographs. Moreover, at least two of the
following criteria were also required: (i) temperature of >38C;
(ii) leukocytosis of >10 000 cells ⁄mm3; and (iii) purulent respir-
atory secretions. Pneumonia was considered to be ventilator-
associated when it occurred after intubation and infection was
judged not to have occurred before an artificial airway was put
in place (in patientsmechanically ventilated formore than 48 h)
[12]. Tracheobronchial secretions and ⁄ or bronchoalveolar
lavage (BAL) specimens were used for microbiological diagno-
sis of pneumonia using non-quantitative culture methods.
Diagnosis of bacteraemia required either growth of a
recognised pathogen from one or more blood cultures, or at
least one of the following signs or symptoms: fever (>38C),
chills, or hypotension and at least one of the following: (a)
common skin contaminant (e.g., diphtheroids, Bacillus sp.,
Propionibacterium sp., coagulase-negative staphylococci or
micrococci) grown from two or more blood cultures drawn
on separate occasions; or (b) common skin contaminant grown
from at least one blood culture from a patient with an
intravascular line and physician-instituted antimicrobial ther-
apy [13]. If bacteraemia was suspected, at least two blood
samples were obtained for culture from separate sites before
the initiation of therapy.
Other infections, such as urinary tract infections and central
venous catheter-related infections, were defined based on the
guidelines issued by the Centers for Disease Control and
Prevention [13]. Septic shock was defined as sepsis with
prolonged hypotension (‡2 h) despite adequate fluid resuscita-
tion, togetherwith the presence of perfusion abnormalities such
as lactic acidosis, oliguria, or acute alteration in mental status.
Outcome measures
The primary endpoint of the study was all-cause in-hospital
mortality. Secondary endpoints included the clinical and
bacteriological outcome of the infection and the occurrence
of adverse events during colistin treatment, and were defined
as follows: clinical cure was defined as resolution of presenting
symptoms and signs of infection by the end of colistin
treatment; clinical improvement was defined as partial resolu-
tion of presenting symptoms and signs of infection; clinical
failure (unresponsiveness) was defined as persistence or
worsening of presenting symptoms and ⁄ or signs of infection
during colistin administration; undetermined was recorded
when clinical assessment was not possible; recurrence of
infection was defined as the occurrence of a new episode of
infection at least 72 h after clinical resolution of a preceding
episode. The evaluation of clinical response was made on the
basis of the resolution of clinical signs and symptoms,
including fever, leukocytosis and improvement of chest
X-rays (for pneumonia).
Bacteriological outcome of the infection was defined as
follows: eradication of the pathogen was defined as no growth of
the pathogen in the final culture of specimens; persistence of the
pathogen was defined as persistent growth of the responsible
pathogen regardless of the clinical outcome of the infection;
recurrence (re-growth) of the pathogen was defined as re-isolation
of the same pathogen regardless of the clinical outcome of the
infection; colonisation was defined as persistence or re-growth
of the pathogen without symptoms and signs of infection;
undetermined was recorded when microbiological assessment
was not possible. Assessment of effectiveness was made at the
end of colistin treatment.
Safety was assessed on the basis of laboratory test results
for renal function (changes from baseline in serum urea and
creatinine levels) during colistin administration. Normal renal
functionwas defined as a serum creatinine level of £1.2 mg ⁄dL.
Acute renal failure was defined as a rise of 2 mg ⁄dL in the
serum creatinine level of patients with previously normal renal
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function. In patients with a history of renal insufficiency, acute
or chronic renal failure was defined as at least a doubling of
the baseline serum creatinine level (defined as the creatinine
level at the initiation of colistin treatment). Organ function was
evaluated daily according to the sequential organ failure
assessment (SOFA) score. For each of the six organ systems
included in the SOFA score (respiratory, cardiovascular,
neurological, renal, haematological and hepatic), organ failure
was defined as a score of = 3 [14]. Prognostic factors possibly
associated with adverse outcome (death) were examined
during the evolution of the infection until the end of colistin
treatment.
Statistical analysis
The chi-square test or Fisher’s exact test for categorical
variables, and the two-sample t-test for continuous variables,
were used for univariate analysis of the association between
clinical characteristics and adverse outcome (death) among
infected patients. Backward stepwise logistic regression ana-
lysis was then conducted to determine independent correlates
of death in infected patients. Variables with p < 0.2 in the
univariate analysis were considered for inclusion in the
multivariate analysis. Analyses were performed with SPSS
v. 10.0 software (SPSS Inc., Chicago, IL, USA). Data were
reported as the mean (±SD), median (range), or odds ratio (OR)
with 95% confidence interval (CI), as appropriate. Significance
was set at p < 0.05.
RESULTS
All patients (n = 43) who received colistin intra-
venously for the treatment of ICU-acquired infec-
tion caused by a Gram-negative bacterium
susceptible only to colistin between 1 July 2001
and 1 December 2003 were studied. During this
period, 4727 adult patients (29.5% females) of
mean age 63.2 (±14.9) years were admitted to the
ICU. These patients had a mean ICU stay of
3.8 days and an ICU mortality rate of 6.5%.
Table 1 shows the demographic and clinical
characteristics for the 43 patients in the study.
Most (86%) patients were male and aged
>50 years (77%). Seven patients were referred to
the ICU from other institutions. Co-morbidity
related directly to the cause of ICU admission was
present in 29 (67.4%) patients. The mean
APACHE II score was 25.8 (±3.7), range 19–35.
This group of patients had a mean ICU and
hospital stay of 61.3 (±41.3) and 78.3 (±50.3) days,
respectively.
All of these patients developed several nosoco-
mial infections preceding the ICU-acquired infec-
tion caused by a multiresistant pathogen. Some
patients developed more than one episode of
infection for which they received treatment. The
patients developed the first ICU-acquired
infection at 5.4 (±0.8) days following ICU admis-
sion. Infections were polymicrobial in 28 (65.1%)
patients. Thirty-eight (88.4%) patients developed
pneumonia, which was ventilator-associated in 32
(84.2%) cases. Fifteen (34.9%) patients developed
bacteraemia; some patients had both bacteraemia
and a specific site infection, mainly pneumonia.
Central venous catheter-related infection, urinary
tract infection and soft tissue infection developed
in 22 (51.2%), ten (23.3%) and five (11.6%)
patients, respectively, while one (2.3%) patient
developed a central nervous system infection. The
following antibiotics were used (usually in com-
bination) for the treatment of these infections: a
third-generation cephalosporin (33 patients), a
quinolone (30), clindamycin (19), an aminoglyco-
side (9), a glycopeptide (7), a carbapenem (7),
metronidazole (4) and penicillin G (2).
During their ICU stay, all patients in the study
developed an ICU-acquired infection caused by a
pathogen (A. baumannii or P. aeruginosa) that was
susceptible only to colistin. Table 2 displays the
characteristics of these infections, most of which
were pneumonia or bacteraemia. Most bacterae-
mias were caused by P. aeruginosa. The antibiotic
spectrum was narrowed following microbiology
results for 20 (46.5%) patients, and changed
because of antibiotic resistance for all patients. All
patients received intravenous colistin therapy. The
mean cumulativedosage of colistin anddurationof
treatment were 141.2 (±75.3) million IU and 18.6
(±5.8) days, respectively. Concomitant antimicro-
bial therapy included a carbapenem (17 patients),
piperacillin-tazobactam (10), ampicillin-sulbactam
Table 1. Demographic and clinical characteristics for the
patients studied (n = 43)
General features Entire group
Male gender, n (%) 37 (86)
Mean age, years (SD) 56.5 (16.2)
Previous surgery, n (%) 6 (13.9)
Underlying disease
Diabetes mellitus 7
Chronic obstructive pulmonary disease 4
Chronic renal dysfunction 5
Non-Hodgkin’s lymphoma 1
Transfer from another institution, n (%) 7 (16.4)
APACHE II score on ICU admission (mean ± SD) 25.8 ± 3.7
Previous antibiotic courses during the same
hospitalisation period, median (range)
4 (2–6)
Number of organ dysfunctions, median (range) 2 (0–4)
Length of stay before isolation of
multiresistant pathogen (sensitive only to colistin)
–associated infection, median (range) (days)
18 (3–64)
Mechanical ventilation for >48 h, n (%) 43 (100)
Total length of ICU stay, median (range) (days) 61 (8–181)
APACHE, Acute Physiology and Chronic Health Evaluation score.
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(2), an aminoglycoside (2) and ciprofloxacin (1).
Concurrently, 14 patients received a glycopeptide
for the treatment of bacteraemia caused by aGram-
positive coccus. In addition, 12 patients received
inotropic drugs for the treatment of septic shock.
No patient received nephrotoxic agents such as
cyclosporin or tacrolimus.
Clinical cure of infection was observed in 30
(69.8%) patients, and clinical improvement in two
(4.7%) patients. Eleven (25.6%) patients did not
respond to colistin treatment (clinical failure); all
of these patients died. In addition, one of two
patients with clinical improvement of the infec-
tion died following cerebral haemorrhage. None
of the patients in the study had a recurrent
nosocomial infection caused by the same multi-
resistant pathogen. Among the 32 patients with
clinical cure or improvement, eradication of the
pathogen was observed in 29 (67.4%) cases, and
colonisation in three cases.
Colistin-associated side-effects, such as pares-
thesias, vertigo, muscle weakness or apnoea, were
not observed. With regard to nephrotoxicity, eight
(18.6%) patients had a documented diagnosis of
chronic renal failure at ICU admission (serum
creatinine >2 mg ⁄dL); of these, five (62.5%)
developed acute or chronic renal failure during
colistin therapy. In addition, two further patients
developed acute renal insufficiency in the ICU
before colistin administration. During colistin
treatment, eight (18.6%) of the 43 patients devel-
oped acute renal failure, including five patients
with chronic renal failure, one of the two patients
who developed acute renal failure before admin-
istration of colistin, and two (6%) of 33 patients
who did not have renal failure at ICU admission
and on initiation of colistin treatment. All of these
patients died. Fig. 1 shows the distribution of
serum creatinine values at the start of colistin
treatment, and the maximum value during treat-
ment and at the end of treatment.
Table 2. Characteristics of infections caused by pathogens
susceptible only to colistin (n = 43)
Type of infection n
Pathogen
PA AB Death
Pneumonia (VAP) 21 14 7 2 (1 with PA + 1 with
AB infection)
Bacteraemia 11 10 1 4 (all with PA infection)
Pneumonia (VAP) and bacteraemia 3 3 2 (all with PA infection)
Pneumonia (VAP) and
catheter-related infection
3 3 2 (all with PA infection)
Pneumonia and urinary tract infection 2 2 1 (with PA infection)
Pneumonia and surgical wound infection 2 2 1 (with AB infection)
Sinusitis 1 1
VAP, ventilator-associated pneumonia; PA, Pseudomonas aeruginosa; AB, Acinetob-
acter baumannii.
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Fig. 1. Distribution of serum creatinine levels on admission to the intensive care unit (ICU), on the first day of colistin
treatment (start), at the peak value (max), and at the end of colistin treatment (end) in the group of patients with normal
baseline creatinine value (a), and in the group of patients with abnormal baseline creatinine value (b). The horizontal line
within the boxes represents the median creatinine baseline value on the first day of colistin treatment.
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Twelve (27.9%) patients died during their
hospitalisation. All deaths occurred in the ICU
(no patients died in the ward following ICU
discharge). Most (91.7%) of these were males. In
nine of the 12 patients with an adverse outcome,
the multiresistant bacterium was isolated from at
least two different sites, while nine patients
developed septic shock, and nine patients had at
least three major organ dysfunctions (12.9% in
survivors). The median ICU stay of these 12
patients was 36 days (range, 8–50 days).
Table 3 shows the results of the univariate
analysis for the factors associated with mortality;
these factors were gender, an age of >50 years,
transfer from another hospital, an APACHE II
score of >30, the presence of more than one organ
dysfunction, septic shock, acute renal failure, and
the length of ICU stay. Multivariate analyses
showed that an age of >50 years (OR, 5.4,
95% CI 1.3–24.9; p < 0.001) and acute renal failure
developed during colistin treatment (OR, 8.2,
95% CI 2.9–23.8; p < 0.001) were independent
predictors of mortality.
DISCUSSION
This study evaluated the effectiveness and safety
of colistin in 43 critically ill patients with ICU-
acquired infections caused by Gram-negative
bacteria that were susceptible only to colistin.
Good clinical response (cure ⁄ improvement) was
observed with 74.4% of patients, and eradication
of the multiresistant Gram-negative pathogen was
obtained for 67.4% of the patients. Acute renal
failure was developed by 18.6% of the patients
during colistin treatment, but mainly by patients
with a history of chronic renal failure. This may
be explained by the fact that potentially nephro-
toxic agents are associated with a higher toxicity
in patients with abnormal renal function, even
with adjusted dosages. In addition, this group of
patients often develops nosocomial infections for
which other potentially nephrotoxic agents may
be used, and has higher acute illness severity
scores than patients with normal renal function
[15]. However, renal function impairment should
not be attributed solely to colistin toxicity as other
factors, e.g., the development of septic shock and
multi-organ failure, may also make a significant
contribution. Indeed, previous studies have
shown that advanced age, severe sepsis, major
surgery, low cardiac output syndrome and hypo-
volaemia are all common conditions associated
with acute renal failure in the ICU setting [16,17].
The observed mortality rate in the present
study was 27.9%, which is no worse than the
mortality reported in studies with comparable
patient groups [18–20]. In keeping with results
from other studies which investigated predictors
of adverse outcome in ICU patients with infection
[21], renal failure was found to be an independent
predictor of death. Considering the fact that
nephrotoxicity is the main adverse reaction of
colistin treatment, it is interesting to note that the
rate of acute renal failure in this patient popula-
tion was 18.6%, which is similar to the rates
reported in studies of ICU patients treated with
antibiotics other than colistin [22].
Clinical experience regarding the use of colistin
in severely ill patients is limited. The overall
favourable response of nosocomial infections
caused by P. aeruginosa and A. baumannii was
60% in a study from Brazil [8], although a major
side-effect observed in that study was renal
insufficiency. In another report from Spain, 21
patients with ventilator-associated pneumonia
caused by bacteria susceptible only to colistin
showed a cure rate of 57% following colistin
treatment [7]. Both of these studies showed higher
mortality rates than the present study. However,
differences in mortality should be interpreted
with caution because of potential differences in
patient characteristics. In addition, there are
differences in the potencies of commercial formu-
lations of colistin in different countries, and this
may translate into differences in efficacy and
safety [23]. In a recent study from New York [9] in
which polymyxin B was used, the mortality rate
was 20% for patients with infections caused by
multiresistant Gram-negative bacteria (much clo-
ser to the results obtained in the present study).
Table 3. Factors associated with adverse clinical outcome
(univariate analysis)
Variable
Adverse
outcome
(n = 12)
Survivors
(n = 31)
Odds
ratio 95% CI p
Female gender 1 5 0.4 0.1–0.7 <0.05
Age >50 years 12 17 5.3 1.8–15.3 <0.01
Transfer from another institution 3 4 1.7 1.1–7.3 <0.05
APACHE II score >30 5 3 2.2 1.4–9.9 <0.05
Presence of >1 organ dysfunction 12 23 1.2 1.1–8.0 <0.05
Septic shock 9 2 8.8 3.1–26.0 <0.01
Acute renal failure 8 0 8.1 2.6–23.9 <0.01
ICU length of stay >40 days 7 20 1.1 1.1–4.8 <0.05
ICU, Intensive care unit.
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Ouderkirk et al. [9] also found that mortality was
considerably higher in patients who developed
renal dysfunction, which is in agreement with the
present results.
Earlier reports showed a high incidence of
colistin toxicity. However, some of these studies
had design defects and involved inappropriate
patient monitoring [5]. In contrast, the present
findings agreed with other reports published
recently [7–9]. Renal injury is the major adverse
effect of colistin. In the largest study to date,
published in 1970, frequently reversible renal
impairment was found in 20% of patients receiv-
ing colistin [24]. This possibility of renal toxicity
should be considered seriously, especially when
colistin is used as a last resort in patients prone to
renal dysfunction because of illness severity
and ⁄ or sepsis.
In an era of continuously increasing rates of
infections with multiresistant pathogens, further
clinical studies should examine the efficacy and
safety of combinations of colistin with other
antibiotics, e.g., carbapenems, ceftazidime and
rifampicin, which may prove synergistic in vivo,
as has been suggested by in-vitro studies [25–27].
In addition, aerosolised colistin may prove bene-
ficial in certain cases of pneumonia in ICU
patients, as has been suggested for patients with
cystic fibrosis; however, it is always necessary to
be aware of the potential for development of
colistin resistance [28].
The present study was not without limitations.
First, the study had the inherent weaknesses of
studies with retrospective design, including the
need to collect data from already completed med-
ical records. Second, the studywas not designed to
specifically investigate the effectiveness of colistin
by providing (for example) comparative outcome
data using a control group of ICU patients with
infection caused by multiresistant Gram-negative
bacilli and treated with a carbapenem following
in-vitro susceptibility test results. Third, the study
cannot provide an estimate for the possible relative
contribution of colistin to renal dysfunction in
patients who developed this complication. Finally,
data on possible side-effects of colistin apart from
nephrotoxicity were not evaluated actively. Nev-
ertheless, several interesting points of clinical
relevance emerged from the study. The results
indicated that colistin can be usedwith satisfactory
efficacy and safety in ICU patients with infections
caused by bacteria which show in-vitro suscepti-
bility only to colistin. However, patients aged
>50 years with rapid deterioration of renal func-
tion of anypathogenesis during colistin therapyare
at high risk for death. In such cases, prophylactic
and ⁄ or intensive renal replacement therapy may
be indicated [29].
In conclusion, colistin appears to be relatively
safe and effective in treating severely ill ICU
patients with infections caused by multiresistant
Gram-negative bacteria. Clinicians should be
vigilant for renal function deterioration during
colistin therapy as this predisposes strongly to an
adverse outcome. However, further investigation
is warranted to further clarify the role of colistin
in the management of critically ill patients with
ICU-acquired infections caused by multiresistant
pathogens.
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